Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN2050 in Lupus Nephritis and IgA Nephropathy
NCT05097989Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial of vemircopan in lupus nephritis (LN) and IgA nephropathy (IgAN) (6 cohorts), sponsored by Alexion Pharmaceuticals. Primary endpoint: Percentage Change in Proteinuria From Baseline at 26 weeks. Started Jan 2022; status: terminated.
02
Drugs
vemircopan
03
Conditions
lupus nephritis (LN)IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05097989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05097989.